Clinical Study ResultsNiagen Bioscience announced positive clinical study results that were recently published in the peer-reviewed journal Aging Cell, highlighting safety and significant increases in NAD+ levels.
Market ExpansionNiagen IV broadens U.S. clinic footprint, poised for further rapid market uptake.
Revenue PerformanceRevenue outperforms expectations, with Niagen Bioscience reporting $30.5M in top-line revenue, exceeding forecasted figures.